上海市第一人民医院，简称市一医院或第一人民医院，由上海申康医院发展中心领导。原址为天主教公济医院，创建于1864年，曾由上海公共租界工部局管理。现全院一共拥有两个院区——北院区位于虹口区武进路85号，南院区位于松江区新松江路650号。

During the past decade, Shanghai General Hospital conducted 115 clinical trials. In the 10-year time frame, 115 clinical trials started and 4 clinical trials were completed, i.e. on average, 3.5% percent of trials that started reached the finish line to date. In the past 5 years, 71 clinical trials started and 3 clinical trials were completed. i.e. 4.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shanghai General Hospital" #1 sponsor was "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine" with 32 trials, followed by "Chengdu Kanghong Biotech Co., Ltd." with 5 trials sponsored, "Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd." with 5 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 4 trials sponsored and "Jiangsu HengRui Medicine Co., Ltd." with 4 trials sponsored. Other sponsors include 64 different institutions and companies that sponsored additional 61 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shanghai General Hospital" #1 collaborator was "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine" with 11 trials as a collaborator, "Ruijin Hospital" with 6 trials as a collaborator, "Changhai Hospital" with 5 trials as a collaborator, "Shanghai Zhongshan Hospital" with 5 trials as a collaborator and "NanoMab Technology (UK) Limited" with 4 trials as a collaborator. Other collaborators include 134 different institutions and companies that were collaborators in the rest 119 trials.

According to Clinical.Site data, the most researched conditions in "Shanghai General Hospital" are "Asthma" (4 trials), "Breast Cancer" (3 trials), "Macular Edema" (3 trials), "Neovascular Age-Related Macular Degeneration" (3 trials) and "Acute Lymphoblastic Leukemia" (2 trials). Many other conditions were trialed in "Shanghai General Hospital" in a lesser frequency.

Most popular intervention types in "Shanghai General Hospital" are "Drug" (84 trials), "Biological" (9 trials), "Device" (6 trials), "Diagnostic Test" (6 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Capecitabine" (5 trials), "Fludarabine" (4 trials), "Oxaliplatin" (3 trials) and "placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Shanghai General Hospital" are 111 trials for "All" genders, 4 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Shanghai General Hospital". 8 are not yet recruiting, 41 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Shanghai General Hospital, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Shanghai General Hospital, 19 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 21 trials that are defined as “Not Applicable".

Shanghai General Hospital has several departments that took part in Clinical trials: "Hematology Department of ShanXi Cancer Hospital" - 3 trials, "Department of Gastroenterology and Hepatology" - 3 trials